Negara: Inggris
Bahasa: Inggris
Sumber: MHRA (Medicines & Healthcare Products Regulatory Agency)
Hexylresorcinol
The Boots Company Plc
R02AA12
Hexylresorcinol
2.4mg
Lozenge
Oromucosal
No Controlled Drug Status
Valid as a prescribable product
BNF: 12030300; GTIN: 5045095918316
Sore Throat Relief Double Action 2.4mg Lozenges Cherry Flavour (Hexylresorcinol) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet Keep this leaflet. You may need to read it again Ask your pharmacist if you need more information or advice If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet You must contact a doctor if your symptoms worsen or do not improve WHAT IS IN THIS LEAFLET 1. What this medicine is and what it is used for 2. Before you take this medicine 3. How to take this medicine 4. Possible side effects 5. How to store this medicine 6. Contents of the pack and other information 1. WHAT THIS MEDICINE IS AND WHAT IT IS USED FOR These lozenges are recommended for sore throats and associated pain. The active ingredient hexylresorcinol is an antiseptic which combats the bacteria that cause sore throats. It also acts as an anaesthetic to bring soothing relief of pain and discomfort. 2. BEFORE YOU TAKE THIS MEDICINE X DO NOT Take these lozenges if you are hypersensitive (allergic) to the active ingredient or any other ingredients in this medicine (listed in section 6) Give to children under 6 years PREGNANCY AND BREAST-FEEDING Ask your doctor or pharmacist for advice before taking any medication. If you are pregnant, or think you may be pregnant, please ask your doctor or pharmacist before using these lozenges. They may not be suitable for you. IMPORTANT INFORMATION ABOUT SOME OF THE INGREDIENTS OF THIS MEDICINE Each lozenge contains a total of 2.4 g of sucrose and glucose. This should be taken into account if you have diabetes mellitus. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking the product. The colour carmoisine (E122) in this medicine may cause allergic reactions 3. HOW TO TAKE THIS MEDIC Baca dokumen lengkapnya
BOOTS SORE THROAT RELIEF DUAL ACTION LOZENGES BLACK CHERRY FLAVOUR Summary of Product Characteristics Updated 20-Aug-2015 | THE BOOTS COMPANY PLC 1. Name of the medicinal product Boots Sore Throat Relief Dual Action Lozenges Black Cherry Flavour 2. Qualitative and quantitative composition Each lozenge contains Hexylresorcinol 2.4mg For excipients see Section 6.1 3. Pharmaceutical form Lozenge A round red lozenge 4. Clinical particulars 4.1 Therapeutic indications As an antiseptic and local anaesthetic for the relief of sore throat and its associated pain. 4.2 Posology and method of administration For oral administration. Adults, the elderly and children 6 years and over: One lozenge dissolved slowly in the mouth every three hours or as required. Do not take more than 12 lozenges in 24 hours. Not to be given to children under 6 years. 4.3 Contraindications Hypersensitivity to any of the ingredients. 4.4 Special warnings and precautions for use The label will convey: Keep out of the reach and sight of children. If symptoms persist consult your doctor. Not to be given to children under 6 years. This product is unsuitable in hereditary fructose intolerance, glucose-galactose malabsorption syndrome, or sucrase-isomaltase deficiency. 4.5 Interaction with other medicinal products and other forms of interaction None known. 4.6 Pregnancy and lactation There is lack of evidence of safety of the product in human pregnancy and in animals, but hexylresorcinol has been used widely in lozenges for many years without apparent ill consequence. However, as with all medicines, caution should be exercised during pregnancy and lactation. 4.7 Effects on ability to drive and use machines None known. 4.8 Undesirable effects None known. REPORTING OF SUSPECTED ADVERSE REACTIONS Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via th Baca dokumen lengkapnya